Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy – ACE Inhibitor Therapy Trial
July 8, 2022
Related
Mirum Reports Positive Phase 3 Study Results Evaluating Chenodal in Patients with CTX
Rare Daily Staff Mirum Pharmaceuticals reported positive data from the phase 3 RESTORE study evaluating Chenodal tablets […]
Read moreSynlogic Raises $21 Million to Advance Late-Stage Pipeline Targeting Rare Metabolic Diseases
Rare Daily Staff Synlogic, a clinical-stage company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care […]
Read moreAmicus Enters into $430 Million Strategic Financing Collaboration with Blackstone
Rare Daily Staff Days after winning U.S. marketing approval of its late-onset Pompe disease therapy, Amicus Therapeutics […]
Read moreNovartis Reports Positive Phase 3 Results for Experimental Therapy to Treat IgAN
Rare Daily Staff Novartis reported positive top-line results from the pre-specified interim analysis of a phase 3 […]
Read moreFDA Launches Pilot Program to Help Further Accelerate Development of Rare Disease Therapies
Rare Daily Staff The U.S. Food and Drug Administration announced a pilot program aimed at accelerating the […]
Read moreCIRM Issues $43.8 Million in Grants to Advance Stem Cell and Gene Therapy
Rare Daily Staff The California Institute for Regenerative Medicine awarded $43.8 million to fund projects aimed at […]
Read moreFDA Lifts Partial Clinical Hold on IND for EryDel’s Phase 3 Therapy for Ataxia-Telangiectasia
Rare Daily Staff Quince Therapeutics said that The U.S. Food and Drug Administration has lifted the partial […]
Read moreFDA Approves Amicus’s New Treatment for Adults with Late-Onset Pompe Disease
Rare Daily Staff The U.S. Food and Drug Administration has approved Amicus Therapeutics’ Pombiliti + Opfolda, a […]
Read moreIonis’s Eplontersen Phase 3 Results Show Consistent and Sustained Benefit in Patients with ATTRv-PN
Rare Daily Staff Ionis Pharmaceuticals reported that The Journal of the American Medical Association published positive results […]
Read more